306 related articles for article (PubMed ID: 29110882)
1. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.
Litwin T; Smoliński Ł; Członkowka A
Neurol Neurochir Pol; 2018; 52(1):98-101. PubMed ID: 29110882
[TBL] [Abstract][Full Text] [Related]
2. Siponimod for the treatment of secondary progressive multiple sclerosis.
Dumitrescu L; Constantinescu CS; Tanasescu R
Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
[TBL] [Abstract][Full Text] [Related]
3. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
6. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
[TBL] [Abstract][Full Text] [Related]
8. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T
Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194
[TBL] [Abstract][Full Text] [Related]
9. Siponimod: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
[TBL] [Abstract][Full Text] [Related]
10. Severe lymphopenia switching from Fingolimod to Siponimod.
Sparaco M; Miele G; Bonavita S
Neurol Sci; 2021 Nov; 42(11):4837-4838. PubMed ID: 34390419
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
12. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Vasiliou S
Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
[TBL] [Abstract][Full Text] [Related]
13. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
14. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
15. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
16. Siponimod (Mayzent)--a new drug for multiple sclerosis.
Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
[No Abstract] [Full Text] [Related]
17. Switching from natalizumab to fingolimod: an observational study.
Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
[TBL] [Abstract][Full Text] [Related]
18. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O
J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738
[TBL] [Abstract][Full Text] [Related]
19. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of reduced fingolimod dosage treatment.
Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
